Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wafermine
- Development stage
- Phase 2
- Lead developer
- Seelos Therapeutics
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
Wafermine is a sublingual racemic ketamine wafer developed by iX Biopharma for the treatment of moderate to severe acute pain and potentially for treatment-resistant depression. It utilizes a patented sublingual delivery technology called WaferiX, which allows for rapid disintegration and absorption of the drug. Wafermine acts as an NMDA receptor antagonist, providing analgesic effects by targeting this receptor.
- Brand names
- Wafermine
- Other names
- Ketamine wafer - iX Biopharma
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on Wafermine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wafermine.